CSIMarket
 
Biomerica Inc   (BMRA)
Other Ticker:  
 
 
Price: $1.0600 $0.03 2.913%
Day's High: $1.08 Week Perf: 0.95 %
Day's Low: $ 1.03 30 Day Perf: 7.06 %
Volume (M): 21 52 Wk High: $ 2.31
Volume (M$): $ 22 52 Wk Avg: $1.21
Open: $1.03 52 Wk Low: $0.70



 Market Capitalization (Millions $) 18
 Shares Outstanding (Millions) 17
 Employees -
 Revenues (TTM) (Millions $) 6
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Biomerica Inc
Biomerica Inc is a California-based medical diagnostic company that develops, manufactures, and distributes diagnostic tests for various diseases and conditions. The company's products cover a wide range of fields, including gastrointestinal, food intolerance, and diabetes. Biomerica's tests are designed to be easy to use, accurate, and cost-effective, making them suitable for use in both clinical settings and at home. The company's goal is to improve healthcare globally by providing accessible and reliable diagnostic solutions.


   Company Address: 17571 Von Karman Avenue Irvine 92614 CA
   Company Phone Number: 645-2111   Stock Exchange / Ticker: NASDAQ BMRA
   BMRA is expected to report next financial results on April 13, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

Gary Huff's Appointment to Biomerica Strategic Advisory Board Signals Promising Future Amidst Challenging Market Conditions

Published Wed, Feb 21 2024 1:19 PM UTC



Biomerica Inc, a leading player in the diagnostics industry, recently welcomed Gary Huff, the former CEO of LabCorp Diagnostics, to its Strategic Advisory Board. The appointment of Mr. Huff, a seasoned executive with extensive experience in medical diagnostics and healthcare, comes at a critical time as the company strives to navigate a difficult first quarter in 2...

Biomerica Inc

Biomerica Inc Shows Improvement in Earnings Despite Revenue Decline

Biomerica Inc, a global provider of advanced medical products, recently reported their financial results for the second quarter of 2024. The company showed a loss of $-0.09 per share, which was an improvement from the loss of $-0.12 per share compared to the same period last year. However, there was a slight increase in shortfall from the previous reporting season, going from $-0.07 per share.
Despite the losses, Biomerica Inc saw a revenue growth of 5.742% to $1.57 million in the second quarter of 2024, up from $1.48 million in the same period last year. However, there was a sequential revenue deterioration of -8.523% from the previous quarter. The company's business surge was short of 11.12% compared to the second quarter of 2023, which was seen across the In Vitro & In Vivo Diagnostic Substances sector.

Product Service News

Biomerica's Revolutionary Hp Detect ELISA Test Receives FDA Clearance, Transforming H. pylori Detection and Redefining Patient Care

Published Mon, Dec 18 2023 12:47 PM UTC

Biomerica's Hp Detect ELISA Test Receives FDA Clearance, Paving the Way for Improved Detection of H. pylori Bacteria
IRVINE, Calif., Dec. 18, 2023 - Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostic products, has achieved a major milestone with its recently granted U.S. Food and Drug Administration (FDA) 510(k) clearance for its Hp...






 

Biomerica Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com